An introduction to physiologically‐based pharmacokinetic models

Abstract

Physiologically-based pharmacokinetic (PBPK) models represent drug kinetics in one or more 'real' organs (and hence require submodels of organs/tissues) and they describe 'whole-body' kinetics by joining together submodels with drug transport by blood flow as dictated by anatomy. They attempt to reproduce 'measureable' physiological and/or pharmacokinetic processes rather than more abstract rate constants and volumes. PBPK models may be built using a 'bottom-up' approach, where parameters are chosen from first principles, literature, or in vitro data as opposed to a 'top-down' approach, where all parameters are estimated from data. The basic principles of PBPK models are described, focusing on the equations for three individual organs: a single flow-limited compartment describing distribution only, a membrane-limited compartment describing distribution, and a single flow-limited compartment with elimination. These organ models are linked to make a basic three-compartment physiological model of the whole body. PBPK models are particularly suited to scaling kinetics across body size (e.g., adult to neonate) and species (e.g., animal to first-in-man) as physiology and pharmacology can be represented by independent parameters. Maturation models can be incorporated as for compartmental models. PBPK models are now available in commercial software packages, and are perhaps now more accessible than ever. Alternatively, even complex PBPK models can be represented in generic differential equation-solving software using the simple principles described here. The relative ease of constructing the code for PBPK models belies the most difficult aspect of their implementation-collecting, collating, and justifying the data used to parameterize the model.

Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review

“…While the latter depends on absolute knowledge of details, which contribute to drug performance in order to predict pharmacokinetics and pharmacodynamics a priori , the former relies completely on already obtained clinical data but may not be able to provide the necessary detail in each case. A ‘middle‐out’ concept that benefits from the combination of the two approaches might offer a sensible compromise when some parameters have not been reliably estimated yet nor need refinement through already available clinical data . Several software platforms enable the building of PBPK models for adults (e.g.…”

Quantitative systems pharmacology and the personalized drug–microbiota–diet axis

“…Pharmacokinetic models quantitatively describe the absorption, distribution, metabolism and elimination (ADME) of a drug to predict the time course of a drug's concentration in the body 24 , 25 . In particular, physiologically based pharmacokinetic (PBPK) models, which compose the core of quantitative systems pharmacology 26 , 27 , describe whole-body drug kinetics by using ordinary differential equations and an organ compartment structure 28 , 29 ( Figure 2 ). These models contain system-specific and drug-specific parameters.…”

An in vitro assay and artificial intelligence approach to determine rate constants of nanomaterial-cell interactions

“…Current methods to determine NM in vivo biodistribution often require animal sacrifice and tissue resection for further processing 10 . This process is time-consuming and requires substantial resources, as often only one time point is available per animal 11 . Simulation-based approaches that incorporate animal physiology 12 , such as physiologically based pharmacokinetic models (PBPK), are a possible solution to this problem as they have proved successful for small molecules 13 .…”